Ribonucleotide reductase subunits M1 and M2 mRNA expression levels and clinical outcome of lung adenocarcinoma patients treated with docetaxel/gemcitabine

J Souglakos*,1,2, I Boukovinas3, M Taron4, P Mendez4, D Mavroudis1,2, M Tripaki1, D Hatzidaki2, A Koutsopoulos5, E Statopoulos5, V Georgoulas1,2 and R Rosell*1,4

1Laboratory of Tumor Cell Biology, School of Medicine, University of Crete, Crete, Greece; 2Department of Medical Oncology, University General Hospital of Heraklion, Crete, Greece; 3Second Department of Medical Oncology, ‘Theagenion’ Cancer Hospital of Thessaloniki, Thessaloniki, Greece; 4Catalan Institute of Oncology, Medical Oncology Service, Hospital Germans Trias i Pujol, Badalona (Barcelona), Spain; 5Department of Pathology, University General Hospital of Heraklion, Crete, Greece

Ribonucleotide reductase subunits M1 (RRM1) and M2 (RRM2) are involved in the metabolism of gemcitabine (2',2'-difluorodeoxycytidine), which is used for the treatment of nonsmall cell lung cancer. The mRNA expression of RRM1 and RRM2 in tumours from lung adenocarcinoma patients treated with docetaxel/gemcitabine was assessed and the results correlated with clinical outcome. RRM1 and RRM2 mRNA levels were determined by quantitative real-time PCR in primary tumours of previously untreated patients with advanced lung adenocarcinoma who were subsequently treated with docetaxel/gemcitabine. Amplification was successful in 42 (79%) of 53 enrolled patients. Low levels of RRM2 mRNA were associated with response to treatment (P < 0.001). Patients with the lowest expression levels of RRM1 had a significantly longer time to progression (P = 0.004) and overall survival (P = 0.02) than patients with the highest levels. Patients with low levels of both RRM1 and RRM2 had a significantly higher response rate (60 vs 14.2%; P = 0.049), time to progression (9.9 vs 2.3 months; P = 0.003) and overall survival (15.4 vs 3.6; P = 0.031) than patients with high levels of both RRM1 and RRM2. Ribonucleotide reductase subunit M1 and RRM2 mRNA expression in lung adenocarcinoma tumours is associated with clinical outcome to docetaxel/gemcitabine. Prospective studies are warranted to evaluate the role of these markers in tailoring chemotherapy.

British Journal of Cancer (2008) 98, 1710–1715. doi:10.1038/sj.bjc.6604344 www.bjcancer.com

Keywords: RRM1; RRM2; lung adenocarcinoma; docetaxel; gemcitabine; pharmacogenomics

Platinum-based chemotherapy is the standard treatment for patients with inoperable locally advanced and metastatic nonsmall cell lung cancer (NSCLC) as it prolongs survival and improves quality of life (Souquet et al, 1993). However, randomised studies have reported no substantial difference in terms of efficacy between various platinum-based regimens using new anticancer drugs (Schiller et al, 2002). Moreover, the toxicity profile of cisplatin can influence the patients’ quality of life. Several randomised phase III studies have demonstrated that nonplatinum-containing regimens have substantial efficacy against advanced/metastatic NSCLC with a more favourable toxicity profile than the corresponding cisplatin-based regimens (Douillard et al, 2001; Georgoulas et al, 2001, 2005; Kosmidis et al, 2002).

Correspondence: Dr R Rosell, Chief, Medical Oncology Service, Scientific Director of Oncology Research, Catalan Institute of Oncology, Hospital Germans Trias i Pujol, Ctra Canyet, sn, 08916 Badalona (Barcelona), Spain; E-mail: rrosell@icodcs.es and Dr J Souglakos, Department of Medical Oncology, University General Hospital of Heraklion, PO Box 1352, Heraklion 71110, Crete, Greece; E-mail: georgsec@meduoc.gr

Received 8 October 2007; revised 10 March 2008; accepted 10 March 2008; published online 15 April 2008

Gemcitabine (2',2'-difluorodeoxycytidine) is a deoxycytidine analogue that is incorporated into DNA and competitively inhibits DNA synthesis (Chabner, 1996). Ribonucleotide reductase (RR) is an enzyme of central importance in DNA synthesis (Cory and Sato, 1983). Ribonucleotide reductase catalyses the conversion of ribonucleotide 5’-diphosphates to their 2'-deoxynucleotide forms, a rate-limiting step in the production of 2'-deoxyribonucleoside 5’-triphosphates (dNTP) required for DNA synthesis (Cory, 1997). The RR holoenzyme consists of M1 (RRM1) and M2 (RRM2) subunits, and the holoenzymatic activity is modulated by levels of the M2 subunit (RRM2) (Tanaka et al, 2000).

RRM1, localised in 11p15.5, also acts as a putative tumour suppressor gene (Pitterle et al, 1999). 11p15.5, also known as LOH11A, is frequently lost in NSCLC, and loss of heterozygosity in this region has been correlated with poor survival in resected NSCLC patients (Bepler et al, 2002). However, RRM1 overexpression was related to gemcitabine resistance in human oropharyngeal epidermoid carcinoma KB cells (Goan et al, 1999). Ribonucleotide reductase subunit M1 mRNA expression by quantitative PCR significantly influenced time to progression and survival in stage IV NSCLC patients treated with gemcitabine/cisplatin (Rosell et al, 2003). Two subsequent studies confirmed that RRM1 mRNA expression levels were able to identify stage IV...
NSCLC patients likely to have good or poor survival when treated with gemcitabine/cisplatin (Rosell et al, 2004; Ceppi et al, 2006).

Ribonucleotide reductase subunit M2 itself is a dimer of two 44-kDa moieties, each containing a tyrosine free radical and nonhaeme iron (Thelander et al, 1985). Cells overexpressing RRM2 exhibit enhanced cellular invasiveness (Zhou et al, 1998), through activation of nuclear factor κB (NF-κB), which increases MMP-9 expression (Duxbury and Whang, 2007). There is limited information concerning the effect of tumoral RRM2 expression and response to gemcitabine in human tumours.

In a randomised multicentre trial comparing docetaxel/cisplatin and docetaxel/gemcitabine as front-line chemotherapy in NSCLC patients, a significantly higher objective response rate was achieved with docetaxel/gemcitabine in adenocarcinoma than in nonadenocarcinoma patients (Georgoulas et al, 2001). To further investigate this issue, we have carried out a multicentre phase II study to evaluate the impact of RRM1 and RRM2 mRNA expression in the tumours of lung adenocarcinoma patients treated with docetaxel/gemcitabine.

MATERIALS AND METHODS

Patients

Chemotherapy-naive patients with inoperable, histologically confirmed stage IIB and IV adenocarcinoma of the lung and Eastern Cooperative Oncology Group performance status (PS) 0–2 were enrolled. Other eligibility criteria were the same as those reported in previous studies (Georgoulas et al, 2001). The study was approved by the ethics and scientific committees of the participating hospitals and was conducted according to the Declaration of Helsinki. All patients gave their signed informed consent prior to study entry. Gemcitabine (Gemzar; Eli Lilly, Indianapolis, IN, USA) (1000 mg·m⁻² on days 1 and 8) and docetaxel (Taxotere; Sanofi-Aventis, Collegeville, NJ, USA) (100 mg·m⁻² on day 8) with human granulocyte colony-stimulating factor support were administered every 3 weeks as previously described (Georgoulas et al, 2001), with dose adjustment if needed due to haematological and nonhaematological toxicity (Georgoulas et al, 2001). Patients were evaluated at baseline and before each third cycle of chemotherapy (Georgoulas et al, 2001).

RRM1 and RRM2 assessment

All paraffin-embedded tumours were reviewed by an independent pathologist to ensure the validity of the specimen and define the most appropriate tumour area for microdissection. From each paraffin block of tumour, serial sections with a thickness of 5 μm were prepared and then stained with nuclear Fast Red (Sigma-Aldrich, St Louis, MO, USA).

RRM1 and RRM2 gene expression analysis was performed in RNA isolated from tumour tissue specimens after laser capture microdissection (Palm, Oberlenheim, Germany), according to a proprietary procedure (patent pending EP05077417.3) of Pangaea Biotech, SA.

The RT-PCR was carried out with the addition of 2.5 μl of template cDNA to 6.25 μl Taqman Universal Master Mix (AB; Applied Biosystems, Foster City, CA, USA) with the addition of specific primers and probe for each gene and adjusted with diethylpyrocarbonate-treated water in a final volume of 12.5 μl per reaction. The primer and probe sets were designed using Primer Express 2.0 Software (AB). Quantification of gene expression was performed using the ABI Prism 7900HT Sequence Detection System (AB). Primers and probe were designed according to the Ref Seq L10342 for RRM1 and NM_001034 for RRM2 (http://www.ncbi.nlm.nih.gov/LocusLink). The primers and 5'-labelled fluorescent reporter dye (6FAM) probe were as follows: RRM1:

1. forward 5'-ACTAAGCACCTGACTATGCTATCC-3', reverse 5'-CTCCTACAACATCAGAACACTT-3', probe 5'-CAACAGATGTGCTGTCCTA-3;
2. forward 5'-CTGTCTCTAACTTTGCA-3', reverse 5'-TAGTTTTTCGCCCTCGTG-3', probe 5'-GAGGAGATCTTCCAGGA-3';
3. β-actin: forward 5'-TGAAGCGGGTCTCACAGTT-3', reverse 5'-GCCATTATGTCAACCCAGATT-3', probe 5'-ACCAACCCGGCGGACCCGG-3'.

Relative gene-expression quantification was performed according to the comparative Ct method using β-actin as an endogenous control and commercial RNA controls (Stratagene, La Jolla, CA, USA) as calibrators. Final results were determined as follows: 2⁻(ΔΔCt sample-ΔΔCt calibrator), where ΔΔCt values of the calibrator and sample are determined by subtracting the Ct value of the target gene from the value of the housekeeping gene, β-actin. In all experiments, only triplicates with a standard deviation (s.d.) of the Ct value <0.20 were accepted. In addition, genomic DNA contamination was excluded by nonreverse transcript RNA for each sample analysed.

Study design

The trial was designed as a prospective phase II trial focused on biomarker analysis in lung adenocarcinoma patients treated with docetaxel/gemcitabine. The primary end point was the overall response rate. The study followed the optimal Simon two-step design. If a minimum objective response rate exceeding 35% was observed in the first 16 patients, 39 additional patients were enrolled in a 2-year (December 2001 to December 2003) time period. Median time to progression and overall survival were calculated from the start of treatment to the first documented disease progression or death, respectively. Quantitative PCR analyses yielded values that were expressed as ratios between two absolute measurements (gene of interest: internal reference gene). Cutoff points were calculated according to median value for the mRNA expression of each gene. Samples with mRNA expression above or equal to the median were considered as samples with high expression, whereas those with value below the median as samples with low expression. In addition, the gene mRNA expression levels were divided in quartiles (Q1: lowest levels) – Q4: highest levels)). Patients in the middle quartiles were considered as one group (Q2 + Q3), and comparisons were performed among all three groups (Q1, Q2 + 3, Q4).

Statistical analyses

The Mann–Whitney t-test was used to test a significant association between the continuous variable of gene expression and the dichotomous variables. Pearson’s exact test was used to evaluate the correlation between RRM1 and RRM2 mRNA expression. The χ² test was used for the association between gene expression and response. Binary logistic regression was carried out to evaluate which of the significant factors in the χ² analysis had a significant influence on response. Cox’s proportional hazards multivariate analysis was used to evaluate which of the significant factors at the univariate analysis had a significant influence on time to progression and overall survival. Logistic regression analysis was used to evaluate which of the significant factors at the univariate analysis had a significant influence on response. Statistical significance was set at P = 0.05.

RESULTS

Patient characteristics

A total of 53 patients were enrolled. Patient characteristics are shown in Table 1. Forty-two (79%) samples were successfully
Genetics and Genomics

RRM1 and RRM2 expression in lung adenocarcinomas

J Souglakos et al

British Journal of Cancer (2008) 98(10), 1710–1715

© 2008 Cancer Research UK

Table I Patient characteristics

| Patients |        |        |
|----------|--------|--------|
| **Gender** |        |        |
| Male     | 45     | 85     |
| Female   | 8      | 15     |
| **Age (years)** |        |        |
| Median   | 60     |        |
| Range    | 39–75  |        |
| **Performance status (ECOG)** |        |        |
| 0        | 35     | 66     |
| I        | 16     | 30     |
| 2        | 2      | 4      |
| **Stage** |        |        |
| IIIB     | 12     | 23     |
| IV       | 41     | 77     |
| **Number of organs involved** |        |        |
| 1        | 16     | 30     |
| 2        | 20     | 38     |
| ≥3       | 17     | 32     |
| **RRM1 mRNA expression** |        |        |
| Samples analysed | 53     | 100    |
| Samples successfully amplified | 42     | 79     |
| Missing values | 11     | 21     |
| **RRM2 mRNA expression** |        |        |
| Samples analysed | 53     | 100    |
| Samples successfully amplified | 42     | 79     |
| Missing values | 11     | 21     |

Abbreviations: ECOG = Eastern Cooperative Oncology Group; RRM1 = ribonucleotide reductase subunit M1; RRM2 = ribonucleotide reductase subunit M2.

Figure 1 Flow chart showing patient progress through the study.

amplified; the remaining 11 samples were not quantifiable because of insufficient tumour tissue or large amounts of necrosis in the tumour sample (Figure 1).

Clinical outcome

In an intent-to-treat analysis, complete response was observed in four (7.5%) and partial response in 15 (28.3%) patients (overall response rate 35.8; 95% confidence interval: 19.6–46.9%). Fifteen (28.3%) patients had stable disease and 20 (37.7%) had progressive disease. There was no correlation between response and known clinical parameters (age, PS, disease stage or the number of involved sites). After a median follow-up period of 7.5 months (range, 0.5–46.2), the median time to progression was 4.3 months (range, 0.2–34.9), and the median overall survival was 10.1 months (range, 0.5–46.2); the 1-year survival rate was 40.2%. For the 42 patients evaluable for RRM1 and RRM2 mRNA expression, overall response rate was 30%, time to progression was 3.9 months and median overall survival was 9.8 months.

RRM1 and RRM2 mRNA expression and clinical outcome

Tumour RRM1 and RRM2 mRNA expression levels ranged from 0.1 to 8.9 (median 1.04; mean 1.8 ± s.d. 1.15) and from 0.97 to 114.3 (median 8.83; mean 17.69 ± s.d. 20.56), respectively. There was no correlation between age, gender, PS or disease stage and RRM1 or RRM2 mRNA levels. Using the median expression levels as cutoff values, high (above or equal to the median) RRM1 mRNA expression was observed in 25 (59.5%) and low (below the median) in 17 (40.5%) patients, and high RRM2 mRNA expression in 22 (52.4%) and low in 20 (47.6%) patients. When patients were divided into quartiles according to their expression levels of RRM1, 11 patients were in the lowest quartile (0.1–0.36), 20 patients in the intermediate quartiles (0.36–2.11) and 11 patients were in the highest quartile (2.11–8.9). When patients were divided into quartiles according to their expression levels of RRM2, 11 patients were in the lowest quartile (0.97–4.03), 20 patients in the intermediate quartiles (4.03–21.75) and 11 in the highest quartile (21.75–114.3) (Table 2).

When patients were divided into those with low vs those with high RRM1 and RRM2 expression, no correlation was found between RRM1 expression and clinical outcome. However, the 20 patients with low RRM2 expression attained a significantly higher response rate than the 22 patients with high RRM2 expression (54.5 vs 9%; \( P = 0.002 \)); there was no significant correlation between RRM2 expression and time to progression or survival (Table 2). When patients were divided by quartiles of RRM1 and RRM2 expression, the 11 patients in the lowest quartile of RRM1 expression had a longer time to progression (7.1 vs 1.7 months; \( P = 0.04 \)) and overall survival (10.6 vs 1.6 months; \( P = 0.02 \)) than the 11 patients in the highest quartile; in addition, there was a nonsignificant trend towards a higher response rate for patients in the lowest quartile, compared to those in the highest quartile (45.5 vs 20%; \( P = 0.062 \)) (Table 2). The 11 patients in the lowest quartile of RRM2 expression attained a significantly higher response rate than the 11 patients in the highest quartile (45.5 vs 0%; \( P = 0.016 \)), but there was no significant difference in time to progression or overall survival according to RRM2 expression quartiles (Table 2).

When patients were classified according to their expression levels of both RRM1 and RRM2, the 10 patients with low levels of both RRM1 and RRM2 attained a higher response rate, time to progression and overall survival than the seven patients with high levels of both genes (response rate: 60 vs 14.2%, \( P = 0.049 \); time to progression: 9.9 vs 2.3 months, \( P = 0.003 \) (Figure 2); overall survival: 15.4 vs 3.6 months, \( P = 0.031 \) (Figure 3)) (Table 2). No other significant correlation was observed between clinical outcome and the combined expression levels of RRM1 and RRM2 mRNA (Table 2).
Univariate and multivariate analyses

The univariate analysis (Table 3) showed that RRM2 mRNA expression was significantly associated with response rate \((P<0.001)\). The multivariate analysis showed that high expression of RRM2 – but not of RRM1 – was significantly associated with poor response (odds ratio: 31.5; \(P=0.002\)) (Table 3). In the univariate and multivariate analyses of survival, only PS emerged as a significant prognostic factor for survival (hazard ratio: 2.26; \(P=0.024\)) (Table 4).

DISCUSSION

The present study has demonstrated for the first time a positive correlation between tumour mRNA expression of RRM2 and response to a gemcitabine-based combination in patients with lung adenocarcinomas. Low RRM2 mRNA expression was associated

| Table 2 | Tumour RRM1 and RRM2 mRNA expression and clinical outcome |
|---------|--------------------------------------------------------|
| Time to progression (months) | Overall survival (months) | Response N (%) |
| N (%) | Median (95% CI) | P | Median (95% CI) | P | CR+PR | SD+PD | P |
| High vs low | Low RRM1 | 17 (40.5) | 4.0 (3.1–5.8) | 0.43 | 9.8 (4.2–15.4) | 0.31 | 7 (41) | 10 (59) | 0.23 |
| | High RRM1 | 25 (59.5) | 3.7 (1.9–5.4) | 5.5 (0.7–10.3) | 0.07 | 6.5 | 0.9 | 6 (24) | 19 (76) | 0.76 |
| | Low RRM2 | 20 (47.6) | 3.6 | 6.8 | 0.38 | 11 (54.5) | 9 (64.5) | 0.002 |
| | High RRM2 | 22 (52.4) | 4.9 | 6.8 | 0.38 | 2 (9) | 19 (91) | 0.19 |
| Quartiles | RRM1 by quartiles | | | | | | | |
| Q1 (low) | 11 | 7.1 (1.8–12.4) | 0.04 | 10.6 (5.6–15.5) | 0.02 | 5 (45.5) | 6 (54.5) | 0.06 |
| Q2+Q3 | 20 | 4.0 (0.8–7.2) | 5.5 (3.8–12.6) | 0.05 | 6 (30) | 70 | NS | 6 (30) | 70 | NS |
| Q4 (high) | 11 | 1.73 (0.6–2.0) | 1.6 (1.4–1.8) | 2 (20) | 80 | 0.01 | 2 | 2 | 0.01 |
| RRM1 and RRM2 | Low RRM1 and low RRM2 | 10 | 9.9 (1.9–17.8) | 0.003 | 5.4 (2.0–14.2) | 0.02 | 5 (45.5) | 6 (54.5) | 0.01 |
| | High RRM1 and low RRM2 | 7 | 2.3 (0–5.3) | 3.6 (0–8.2) | 1 (12) | 6 (58) | 0.09 | 6 (30) | 70 | 0.06 |
| | Low RRM1 and high RRM2 | 15 | 3.6 (0.32–6.8) | 0.1 | 6.4 (4.4–8.3) | 0.17 | 3 (20) | 12 (80) | 0.06 |
| | High RRM1 and low RRM2 | 10 | 3.8 (0–7.2) | 4.9 (1.0–9.3) | 1.5 | 3 (30) | 7 (70) | 0.06 |

Abbreviations: CI = confidence interval; CR = complete response; PD = progressive disease; PR = partial response; SD = stable disease; RRM1 = ribonucleotide reductase subunit M1; RRM2 = ribonucleotide reductase subunit M2. *P-value: Q1 vs Q4. **P-value: Q1 vs Q2+3 and Q2+3 vs Q4. ***P-value: Q2+3 vs Q4. ****P-value: both low vs both high. Both low vs RRM1 low/RRM2 high or RRM1 high/RRM2 low.

Table 3 | Univariate and multivariate analyses for response |
|-----------------|-----------------|-----------------|
| Odds ratio | 95% CI | P-value |
| Univariate analysis | | | |
| Age (≤65 vs >65 years) | 1.01 | 0.69–1.34 | 0.97 |
| Gender (male vs female) | 1.23 | 0.76–1.43 | 0.64 |
| Performance status (0 vs 1–2) | 3.54 | 0.97–2.04 | 0.15 |
| Stage (III vs IV) | 1.12 | 0.67–1.41 | 0.42 |
| RRM1 mRNA (low vs high) | 1.38 | 0.67–2.91 | 0.31 |
| RRM2 mRNA (high vs low) | 3.75 | 3.8–369.8 | <0.001 |
| Multivariate analysis | 31.5 | 3.5–283.3 | 0.002 |

Abbreviations: CI = confidence interval; RRM1 = ribonucleotide reductase subunit M1; RRM2 = ribonucleotide reductase subunit M2.
with a significantly higher response rate compared to that of patients with high RRM2 mRNA expression. In fact, only two (9%) of 22 patients with high RRM2 expression responded to docetaxel/gemcitabine. Furthermore, the multivariate analysis revealed that RRM2 expression was an independent marker for response ($P = 0.002$). The probability of response in patients with low RRM2 expression was 31.5% higher than that of patients with high RRM2 expression. In addition, patients with RRM1 mRNA expression in the lowest quartile attained a significantly higher time to progression ($P = 0.044$) and overall survival ($P = 0.02$) and showed a trend towards a higher response rate ($P = 0.06$), compared to patients in the highest quartile of RRM1 expression. Furthermore, patients with low expression of both RRM1 and RRM2 derived the maximum benefit from docetaxel/gemcitabine, with a significantly higher response rate ($P = 0.049$), time to progression ($P = 0.003$) and overall survival ($P = 0.031$). Despite the fact that caution is needed when interpreting these results, due to the small number of patients evaluated, our data suggest that the molecular profile of the primary tumour could be used as a marker for response and clinical outcome of patients with lung adenocarcinomas treated with docetaxel/gemcitabine.

The results of the present study are along the lines of several other reports demonstrating that tumour mRNA expression of RRM1 was correlated with clinical response to gemcitabine/cisplatin in stage IV NSCLC (Rosell et al., 2003, 2004; Ceppi et al., 2006). In addition, inhibition of RRM2 mRNA expression in vitro with the use of interference RNA enhanced chemosensitivity of pancreatic adenocarcinomas to gemcitabine (Duxbury et al., 2003, 2004). Apart from the well-known role of RRM2 in maintaining tumour DNA integrity, several studies have reported that RRM2 has additional functions that influence the invasive phenotype. Increased RRM1 and RRM2 activity was identified in highly metastatic tumour cells (Schallreuter et al., 1992), whereas overexpression of RRM2 in human oral carcinoma cells was shown to be associated with increased invasive potential (Zhou et al., 1998), probably through NF-kB and MMP-9 (Duxbury and Whang, 2007). In conclusion, the results of the present study revealed that the efficacy of docetaxel/gemcitabine in lung adenocarcinoma patients is associated with RRM1 and RRM2 mRNA expression, thus indicating the importance of tailoring treatment. As this study was conducted in patients with lung adenocarcinomas, it is unclear whether these observations are also valid in patients with squamous cell carcinomas, and the sample size in the present study requires the results to be interpreted with caution. The role of RRM1 and RRM2 should be further investigated in an adequately statistically powered, independent set of samples. In addition, prospective studies using gemcitabine, either as a single agent or in combination with other drugs, are warranted to further clarify the relation between RRM1 and RRM2 coexpression and tumour chemosensitivity. The potential predictive role of RRM1 and RRM2 mRNA expression warrants examination in malignancies where gemcitabine-based therapy is standard, such as pancreatic cancer. Finally, prospective studies are warranted to clarify the importance of RRM1 and RRM2 expression for tailoring treatment of patients with NSCLC.

**ACKNOWLEDGEMENTS**

This work was partly supported by the Cretan Association for Biomedical Research (CABR). Dr John Souglakos is the recipient of a CABR research fellowship.

**REFERENCES**

Bepler G, Gautam A, McIntyre LM, Beck AF, Chervinsky DS, Kim YC, Pitterle DM, Hyland A (2002) Prognostic significance of molecular genetic aberrations on chromosome segment 11p15.5 in non-small-cell lung cancer. *J Clin Oncol* 20: 1353–1360.

Ceppi P, Volante M, Novello S, Rapa I, Danenberg KD, Danenberg PV, Cambieri A, Selvaggi G, Saviozzi S, Calogero R, Papotti M, Scagliotti GV (2006) ERCC1 and RRM1 gene expression but not EGFR are predictive of shorter survival in advanced non-small-cell lung cancer treated with cisplatin and gemcitabine. *Ann Oncol* 17: 1818–1825.

Cory JG (1997) Purine and pyrimidine nucleotide metabolism. In *Biochemistry with Clinical Correlations*, DenVen T (ed) Wiley-Liss: New York, pp 823–860.

Cory JG, Sato A (1983) Regulation of ribonucleotide reductase activity in mammalian cells. *Mol Cell Biochem* 53–54: 257–266.

Chabner B (1996) Cytidine analogues. In *Cancer Chemotherapy and Biotherapy: Principles and Practice*, Chabner B and Longo D (eds) pp 825–860 New York, pp 823–860.

Douillard JY, Lerrode D, Monnier A, Bennouna J, Haller AM, Sun XS, Assouline D, Grau B, Riviere A (2001) Combined paclitaxel and gemcitabine as first-line treatment in metastatic non-small cell lung cancer: a multicentre phase II study. *Br J Cancer* 84: 1179–1184.

Duxbury MS, Ito H, Benoit E, Zinner MJ, Ashley SW, Whang EE (2003) RNA interference targeting focal adhesion kinase enhances pancreatic adenocarcinoma gemcitabine chemosensitivity. *Biochem Biophys Res Commun* 311: 786–792.

Duxbury MS, Whang EE (2007) RRM2 induces NF-kappaB-dependent MMP-9 activation and enhances cellular invasiveness. *Biochem Biophys Res Commun* 354: 190–196.

Georgoulas V, Ardanavis A, Tsifakaki X, Agelidou A, Mixalopoulo P, Anagnostopoulou O, Ziotopoulos P, Toubis M, Syrigos K, Samaras N, Polyzos A, Christou A, Kakolyris S, Kouroussis C, Androutsakis N, Samonis G, Chatzidaki-D (2005) Vinorelbine plus cisplatin versus docetaxel plus gemcitabine in advanced non-small-cell lung cancer: a phase III randomized trial. *J Clin Oncol* 23: 2937–2945.

Georgoulas V, Papadakis E, Alexopoulos A, Tsifakaki X, Rapti A, Veslemes M, Palamidas P, Vlachonikolis I (2001) Platinum-based and non-platinum-based chemotherapy in advanced non-small-cell lung cancer: a randomised multicentre trial. *Lancet* 357: 1478–1484.

Goan YG, Zhou B, Hu E, Mi S, Yen Y (1999) Overexpression of ribonucleotide reductase as a mechanism of resistance to 2,2-difluorodeoxycytidine in the human KB cancer cell line. *Cancer Res* 59: 4204–4207.

Kosmidis P, Mylonakis N, Nicolaides G, Kalophonos C, Samantas E, Boukoinas J, Fountzilas G, Sklaros D, Economopoulos T, Tsavdaridis D, Papakostas P, Bacoianis C, Dimopoulos M (2002) Paclitaxel plus carboplatin versus gemcitabine plus paclitaxel in advanced non-small-cell lung cancer: a phase III randomized trial. *J Clin Oncol* 20: 3578–3585.
Pitterle DM, Kim YC, Jolicoeur EM, Gao Y, O’Briant KC, Bepler G (1999)
Lung cancer and the human gene for ribonucleotide reductase subunit
M1 (RRM1). *Mamm Genome* 10: 916 – 922
Rosell R, Danenberg KD, Alberola V, Bepler G, Sanchez JJ, Camps C,
Provencio M, Isla D, Taron M, Diz P, Artal A (2004) Ribonucleotide
reductase messenger RNA expression and survival in gemcitabine/
cisplatin-treated advanced non-small cell lung cancer patients. *Clin
Cancer Res* 10: 1318 – 1325
Rosell R, Scagliotti G, Danenberg KD, Lord RV, Bepler G, Novello S, Cooc J,
Crino L, Sanchez JJ, Taron M, Boni C, De Marinis F, Tonato M,
Marangolo M, Gozzelino F, Di Costanzo F, Rinaldi M, Salonga D,
Stephens C (2003) Transcripts in pretreatment biopsies from a three-arm
randomized trial in metastatic non-small-cell lung cancer. *Oncogene* 22:
3548 – 3553
Schallreuter KU, Elgren TE, Nelson Jr LS, MacFarlan S, Yan-Sze I,
Hogenkamp HP (1992) Ribonucleotide diphosphate reductase from
human metastatic melanoma. *Melanoma Res* 2: 393 – 400
Schiller JH, Harrington D, Belani CP, Langer C, Sandler A, Krook J, Zhu J,
Johnson DH (2002) Comparison of four chemotherapy regimens for
advanced non-small-cell lung cancer. *N Engl J Med* 346: 92 – 98
Souquet PJ, Chauvin F, Boissel JP, Celleroino R, Cormier Y, Ganz PA, Kaasa
S, Pater JL, Quoix E, Rapp E *et al.* (1993) Polychemotherapy in advanced
non small cell lung cancer: a meta-analysis. *Lancet* 342: 19 – 21
Tanaka H, Arakawa H, Yamaguchi T, Shiraishi K, Fukuda S, Matsui K,
Takei Y, Nakamura Y (2000) A ribonucleotide reductase gene involved in a
p53-dependent cell-cycle checkpoint for DNA damage. *Nature* 404:
42 – 49
Thelander M, Graslund A, Thelander L (1985) Subunit M2 of mammalian
ribonucleotide reductase. Characterization of a homogeneous
protein isolated from M2-overproducing mouse cells. *J Biol Chem* 260:
2737 – 2741
Zhou BS, Tsai P, Ker R, Tsai J, Ho R, Yu J, Shih J, Yen Y (1998)
Overexpression of transfected human ribonucleotide reductase M2
subunit in human cancer cells enhances their invasive potential. *Clin
Exp Metastasis* 16: 43 – 49